(Q40064850)

17 September 2017

title

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer (English)

1 reference

17 September 2017

1 reference

1 reference

1 reference

6

Akseli Hemminki

1 reference

17 September 2017

7

Anna Kanerva

1 reference

17 September 2017

Mari Raki

1

1 reference

17 September 2017

Merja Särkioja

2

1 reference

17 September 2017

Renee A Desmond

3

1 reference

17 September 2017

Dung-Tsa Chen

4

1 reference

17 September 2017

Ralf Bützow

5

1 reference

17 September 2017

language of work or name

English

0 references

publication date

22 October 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

108

1 reference

17 September 2017

issue

1

1 reference

17 September 2017

page(s)

166-172

1 reference

17 September 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Targeted gene therapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Gene transfer approaches for gynecological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Adenoviruses for treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Studies on the use of viruses in the treatment of carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Cellular targets for transformation by the adenovirus E1A proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.09.013

10.1016/J.YGYNO.2007.09.013

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference